| Field | Specification |
|---|---|
| Target | |
| Alternative names | Myomegalin; Cardiomyopathy-associated protein 2; Phosphodiesterase 4D-interacting protein; PDE4DIP; CMYA2; KIAA0454; KIAA0477; MMGL |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human PDE4DIP recombinant protein (Position: Q96-M1254). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes myomegalin (gene PDE4DIP) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 265.1 kDa, and the supplier reports an observed band at about 150 kDa.
Myomegalin (PDE4DIP) is a large coiled-coil protein first identified as a partner of PDE4D that anchors cAMP signaling components to the Golgi and centrosome. Certain isoforms work with AKAP9 and CDK5RAP2 to promote microtubule nucleation and to tether non-centrosomal microtubules to the Golgi, supporting polarized cell migration and spindle orientation.
| Target | Myomegalin (gene PDE4DIP; UniProt Q5VU43, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 265.1 kDa |
| Observed MW | 150 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human HEK293 cells, human K562 cells, human U-87MG cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human colorectal cancer tissue, human placenta tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): MCF-7 cells.
Samples with a confirmed signal (flow cytometry): A549 cells.
Immunogen
Recombinant human PDE4DIP fragment (Gln96–Met1254), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places myomegalin in the Golgi apparatus and SUBCELLULAR LOCATION:. Tissue expression noted by UniProt (human): Highly expressed in adult and fetal heart, in skeletal muscle and, to a lower extent, in brain and placenta. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
